Physician profile
Alexander B Snyder
NPI 1275502320
$3,743.29
in general payments reported to CMS, 2019-2025
25 companies · $68.46 in 2025
The $68.46 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $169 · 2021: $532 · 2022: $1,176 · 2023: $838 · 2024: $154 · 2025: $68.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $553.04 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $541.26 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Preventric Diagnostics, INC. | $502.44 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.76 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $203.09 | 2019-2024 | Breztri, Airsupra |
| Allergan, INC. | $196.67 | 2019-2021 | |
| Pfizer INC. | $183.99 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $160.57 | 2023-2024 | Rexulti |
| Sun Pharmaceutical Industries INC. | $144.08 | 2023 | Cequa |
| Lilly USA, LLC | $134.90 | 2019-2023 | Mounjaro, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $128.10 | 2022-2024 | |
| Biotissue Holdings INC. | $120.95 | 2022 | |
| Janssen Pharmaceuticals, INC | $113.72 | 2020-2023 | Xarelto |
| Mylan Specialty L.P. | $109.01 | 2019-2022 | |
| Dompe US, INC. | $101.85 | 2024-2025 | Oxervate |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $91.35 | 2022-2023 | Vraylar |
| Astellas Pharma US INC | $87.32 | 2019-2021 | |
| Exact Sciences Corporation | $39.87 | 2023 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $26.16 | 2019-2020 | |
| Abbott Laboratories | $24.04 | 2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $16.13 | 2019 | |
| Paratek Pharmaceuticals, INC. | $15.11 | 2024 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.57 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.35 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.